{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T21:05:09Z","timestamp":1791147909849,"version":"4.1.0"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2010,2,19]],"date-time":"2010-02-19T00:00:00Z","timestamp":1266537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1007\/s00228-010-0793-6","type":"journal-article","created":{"date-parts":[[2010,2,18]],"date-time":"2010-02-18T08:59:08Z","timestamp":1266483548000},"page":"537-545","source":"Crossref","is-referenced-by-count":85,"title":["The pharmacological treatment of opioid addiction\u2014a clinical perspective"],"prefix":"10.1007","volume":"66","author":[{"given":"Philipp","family":"Lobmaier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gossop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helge","family":"Waal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgen","family":"Bramness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,2,19]]},"reference":[{"key":"793_CR1","volume-title":"The state of the drugs problem in Europe","author":"EMCDDA","year":"2008","unstructured":"EMCDDA (2008) The state of the drugs problem in Europe. European Monitoring Centre for Drugs and Drug Addiction, Lisbon"},{"issue":"2","key":"793_CR2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/35053570","volume":"2","author":"EJ Nestler","year":"2001","unstructured":"Nestler EJ (2001) Molecular basis of long-term plasticity underlying addiction. Nat Rev Neurosci 2(2):119\u2013128","journal-title":"Nat Rev Neurosci"},{"issue":"Suppl 2","key":"793_CR3","doi-asserted-by":"crossref","first-page":"S91","DOI":"10.1046\/j.1360-0443.95.8s2.19.x","volume":"95","author":"TE Robinson","year":"2000","unstructured":"Robinson TE, Berridge KC (2000) The psychology and neurobiology of addiction: an incentive-sensitization view. Addiction 95(Suppl 2):S91\u2013S117","journal-title":"Addiction"},{"key":"793_CR4","volume-title":"Opioid addiction and treatment","author":"DD Simpson","year":"1990","unstructured":"Simpson DD, Sells SB (1990) Opioid addiction and treatment. Robert E. Krieger, Malabar"},{"key":"793_CR5","doi-asserted-by":"crossref","unstructured":"Gowing L, Farrell M, Ali R, White JM (2009) Alpha2-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2:CD002024. doi: 10.1002\/14651858.CD002024.pub3","DOI":"10.1002\/14651858.CD002024.pub3"},{"key":"793_CR6","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1749-6632.2000.tb06683.x","volume":"909","author":"MJ Kreek","year":"2000","unstructured":"Kreek MJ (2000) Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine. Ann N Y Acad Sci 909:186\u2013216","journal-title":"Ann N Y Acad Sci"},{"key":"793_CR7","doi-asserted-by":"crossref","unstructured":"Amato L, Davoli M, Minozzi S, Ali R, Ferri M (2005) Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 3:CD003409. doi: 10.1002\/14651858.CD003409.pub3","DOI":"10.1002\/14651858.CD003409.pub3"},{"key":"793_CR8","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1192\/bjp.154.3.360","volume":"154","author":"M Gossop","year":"1989","unstructured":"Gossop M, Griffiths P, Bradley B, Strang J (1989) Opiate withdrawal symptoms in response to 10-day and 21-day methadone withdrawal programmes. Br J Psychiatry 154:360\u2013363","journal-title":"Br J Psychiatry"},{"issue":"6","key":"793_CR9","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/0306-4603(90)90054-2","volume":"15","author":"J Strang","year":"1990","unstructured":"Strang J, Gossop M (1990) Comparison of linear versus inverse exponential methadone reduction curves in the detoxification of opiate addicts. Addict Behav 15(6):541\u2013547","journal-title":"Addict Behav"},{"key":"793_CR10","doi-asserted-by":"crossref","unstructured":"Gowing L, Ali R, White JM (2009) Buprenorphine for the management of opioid withdrawal. Cochrane Database Syst Rev 3:CD002025. doi: 10.1002\/14651858.CD002025.pub4","DOI":"10.1002\/14651858.CD002025.pub4"},{"issue":"2","key":"793_CR11","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/JCP.0b013e318032ec2a","volume":"27","author":"LJ Reed","year":"2007","unstructured":"Reed LJ, Glasper A, de Wet CJ, Bearn J, Gossop M (2007) Comparison of buprenorphine and methadone in the treatment of opiate withdrawal: possible advantages of buprenorphine for the treatment of opiate-benzodiazepine codependent patients? J Clin Psychopharmacol 27(2):188\u2013192","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"793_CR12","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/0376-8716(88)90078-6","volume":"21","author":"M Gossop","year":"1988","unstructured":"Gossop M (1988) Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend 21(3):253\u2013259","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"793_CR13","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/S0376-8716(99)00116-7","volume":"59","author":"N Buntwal","year":"2000","unstructured":"Buntwal N, Bearn J, Gossop M, Strang J (2000) Naltrexone and lofexidine combination treatment compared with conventional lofexidine treatment for in-patient opiate detoxification. Drug Alcohol Depend 59(2):183\u2013188","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"793_CR14","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0376-8716(98)00030-1","volume":"50","author":"J Bearn","year":"1998","unstructured":"Bearn J, Gossop M, Strang J (1998) Accelerated lofexidine treatment regimen compared with conventional lofexidine and methadone treatment for in-patient opiate detoxification. Drug Alcohol Depend 50(3):227\u2013232","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"793_CR15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1080\/105504999305749","volume":"8","author":"J Strang","year":"1999","unstructured":"Strang J, Bearn J, Gossop M (1999) Lofexidine for opiate detoxification: review of recent randomised and open controlled trials. Am J Addict 8(4):337\u2013348","journal-title":"Am J Addict"},{"issue":"1","key":"793_CR16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1080\/09595239996789","volume":"18","author":"J Bearn","year":"1999","unstructured":"Bearn J, Gossop M, Strang J (1999) Rapid opiate detoxification treatments. Drug Alcohol Rev 18(1):75\u201381","journal-title":"Drug Alcohol Rev"},{"issue":"8","key":"793_CR17","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jama.294.8.903","volume":"294","author":"ED Collins","year":"2005","unstructured":"Collins ED, Kleber HD, Whittington RA, Heitler NE (2005) Anesthesia-assisted vs buprenorphine-or clonidine-assisted heroin detoxification and naltrexone induction: a randomized trial. JAMA 294(8):903\u2013913","journal-title":"JAMA"},{"key":"793_CR18","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1192\/bjp.161.5.654","volume":"161","author":"S Unnithan","year":"1992","unstructured":"Unnithan S, Gossop M, Strang J (1992) Factors associated with relapse among opiate addicts in an out-patient detoxification programme. Br J Psychiatry 161:654\u2013657","journal-title":"Br J Psychiatry"},{"issue":"1","key":"793_CR19","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1081\/ADA-100103117","volume":"27","author":"MA Chutuape","year":"2001","unstructured":"Chutuape MA, Jasinski DR, Fingerhood MI, Stitzer ML (2001) One-, three-, and six-month outcomes after brief inpatient opioid detoxification. Am J Drug Alcohol Abuse 27(1):19\u201344","journal-title":"Am J Drug Alcohol Abuse"},{"issue":"7396","key":"793_CR20","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1136\/bmj.326.7396.959","volume":"326","author":"J Strang","year":"2003","unstructured":"Strang J, McCambridge J, Best D, Beswick T, Bearn J, Rees S et al (2003) Loss of tolerance and overdose mortality after inpatient opiate detoxification: follow up study. BMJ 326(7396):959\u2013960","journal-title":"BMJ"},{"issue":"9148","key":"793_CR21","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S0140-6736(98)05356-2","volume":"353","author":"J Ward","year":"1999","unstructured":"Ward J, Hall W, Mattick RP (1999) Role of maintenance treatment in opioid dependence. Lancet 353(9148):221\u2013226","journal-title":"Lancet"},{"issue":"8","key":"793_CR22","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1046\/j.1360-0443.2002.00179.x","volume":"97","author":"MC Buster","year":"2002","unstructured":"Buster MC, van Brussel GH, Van den Brink W (2002) An increase in overdose mortality during the first 2\u00a0weeks after entering or re-entering methadone treatment in Amsterdam. Addiction 97(8):993\u20131001","journal-title":"Addiction"},{"issue":"1","key":"793_CR23","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1080\/00952990802342899","volume":"35","author":"YP Bao","year":"2009","unstructured":"Bao YP, Liu ZM, Epstein DH, Du C, Shi J, Lu L (2009) A meta-analysis of retention in methadone maintenance by dose and dosing strategy. Am J Drug Alcohol Abuse 35(1):28\u201333","journal-title":"Am J Drug Alcohol Abuse"},{"key":"793_CR24","doi-asserted-by":"crossref","unstructured":"Faggiano F, Vigna-Taglianti F, Versino E, Lemma P (2003) Methadone maintenance at different dosages for opioid dependence. Cochrane Database Syst Rev 3:CD002208. doi: 10.1002\/14651858.CD002208","DOI":"10.1002\/14651858.CD002208"},{"key":"793_CR25","unstructured":"WHO (2009) Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. http:\/\/whqlibdoc.who.int\/publications\/2009\/9789241547543_eng.pdf . Accessed 16 January 2010"},{"key":"793_CR26","doi-asserted-by":"crossref","unstructured":"Mattick RP, Breen C, Kimber J, Davoli M (2009) Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 3:CD002209. doi: 10.1002\/14651858.CD002209.pub2","DOI":"10.1002\/14651858.CD002209.pub2"},{"issue":"4","key":"793_CR27","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.jsat.2005.02.007","volume":"28","author":"L Amato","year":"2005","unstructured":"Amato L, Davoli M, Perucci A, Ferri M, Faggiano F, Mattick P (2005) An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 28(4):321\u2013329","journal-title":"J Subst Abuse Treat"},{"issue":"4","key":"793_CR28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1046\/j.1360-0443.1998.9345157.x","volume":"93","author":"LA Marsch","year":"1998","unstructured":"Marsch LA (1998) The efficacy of methadone maintenance interventions in reducing illicit opiate use, HIV risk behavior and criminality: a meta-analysis. Addiction 93(4):515\u2013532","journal-title":"Addiction"},{"issue":"2","key":"793_CR29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1360-0443.1994.tb00879.x","volume":"89","author":"JR Caplehorn","year":"1994","unstructured":"Caplehorn JR, Dalton MS, Cluff MC, Petrenas AM (1994) Retention in methadone maintenance and heroin addicts\u2019 risk of death. Addiction 89(2):203\u2013209","journal-title":"Addiction"},{"issue":"3","key":"793_CR30","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0376-8716(00)00211-8","volume":"62","author":"M Gossop","year":"2001","unstructured":"Gossop M, Marsden J, Stewart D, Treacy S (2001) Outcomes after methadone maintenance and methadone reduction treatments: two-year follow-up results from the National Treatment Outcome Research Study. Drug Alcohol Dep 62(3):255\u2013264","journal-title":"Drug Alcohol Dep"},{"key":"793_CR31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1471-2458-8-43","volume":"8","author":"I Skeie","year":"2008","unstructured":"Skeie I, Brekke M, Lindbaek M, Waal H (2008) Somatic health among heroin addicts before and during opioid maintenance treatment: a retrospective cohort study. BMC Public Health 8:43","journal-title":"BMC Public Health"},{"issue":"1\u20133","key":"793_CR32","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.drugalcdep.2007.11.003","volume":"94","author":"T Clausen","year":"2008","unstructured":"Clausen T, Anchersen K, Waal H (2008) Mortality prior to, during and after opioid maintenance treatment (OMT): a national prospective cross-registry study. Drug Alcohol Depend 94(1\u20133):151\u2013157","journal-title":"Drug Alcohol Depend"},{"issue":"9158","key":"793_CR33","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/S0140-6736(05)76462-X","volume":"353","author":"M Torrens","year":"1999","unstructured":"Torrens M, Domingo-Salvany A, Alonso J, Castillo C, San L (1999) Methadone and quality of life. Lancet 353(9158):1101","journal-title":"Lancet"},{"issue":"9","key":"793_CR34","first-page":"1049","volume":"6","author":"DS Metzger","year":"1993","unstructured":"Metzger DS, Woody GE, McLellan AT, O\u2019Brien CP, Druley P, Navaline H et al (1993) Human immunodeficiency virus seroconversion among intravenous drug users in-and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 6(9):1049\u20131056","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"3","key":"793_CR35","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0740-5472(03)00130-2","volume":"25","author":"RL Hubbard","year":"2003","unstructured":"Hubbard RL, Craddock SG, Anderson J (2003) Overview of 5-year followup outcomes in the drug abuse treatment outcome studies (DATOS). J Subst Abuse Treat 25(3):125\u2013134","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"793_CR36","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1046\/j.1360-0443.2003.00296.x","volume":"98","author":"M Gossop","year":"2003","unstructured":"Gossop M, Marsden J, Stewart D, Kidd T (2003) The National Treatment Outcome Research Study (NTORS): 4\u20135\u00a0year follow-up results. Addiction 98(3):291\u2013303","journal-title":"Addiction"},{"issue":"1","key":"793_CR37","first-page":"62","volume":"68","author":"S Magura","year":"2001","unstructured":"Magura S, Rosenblum A (2001) Leaving methadone treatment: lessons learned, lessons forgotten, lessons ignored. Mt Sinai J Med 68(1):62\u201374","journal-title":"Mt Sinai J Med"},{"issue":"12","key":"793_CR38","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1001\/archinte.166.12.1280","volume":"166","author":"GB Ehret","year":"2006","unstructured":"Ehret GB, Voide C, Gex-Fabry M, Chabert J, Shah D, Broers B et al (2006) Drug-induced long QT syndrome in injection drug users receiving methadone: high frequency in hospitalized patients and risk factors. Arch Intern Med 166(12):1280\u20131287","journal-title":"Arch Intern Med"},{"issue":"1","key":"793_CR39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1159\/000081416","volume":"11","author":"I Maremmani","year":"2005","unstructured":"Maremmani I, Pacini M, Cesaroni C, Lovrecic M, Perugi G, Tagliamonte A (2005) QTc interval prolongation in patients on long-term methadone maintenance therapy. Eur Addict Res 11(1):44\u201349","journal-title":"Eur Addict Res"},{"issue":"6","key":"793_CR40","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1360-0443.2009.02549.x","volume":"104","author":"K Anchersen","year":"2009","unstructured":"Anchersen K, Clausen T, Gossop M, Hansteen V, Waal H (2009) Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction 104(6):993\u2013999","journal-title":"Addiction"},{"issue":"1","key":"793_CR41","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0376-8716(03)00187-X","volume":"72","author":"KA Dolan","year":"2003","unstructured":"Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD (2003) A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend 72(1):59\u201365","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"793_CR42","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0095-5108(18)30077-0","volume":"26","author":"SR Kandall","year":"1999","unstructured":"Kandall SR, Doberczak TM, Jantunen M, Stein J (1999) The methadone-maintained pregnancy. Clin Perinatol 26(1):173\u2013183","journal-title":"Clin Perinatol"},{"key":"793_CR43","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1159\/000210042","volume":"15","author":"B Bakstad","year":"2009","unstructured":"Bakstad B, Sarfi M, Welle-Strand G, Ravndal E (2009) Opioid maintenance treatment during pregnancy: occurrence and severity of neonatal abstinence syndrome. Eur Addict Res 15:128\u2013134","journal-title":"Eur Addict Res"},{"issue":"1","key":"793_CR44","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0022-3565(25)10510-7","volume":"274","author":"SL Walsh","year":"1995","unstructured":"Walsh SL, Preston KL, Bigelow GE, Stitzer ML (1995) Acute administration of buprenorphine in humans: partial agonist and blockade effects. J Pharmacol Exp Ther 274(1):361\u2013372","journal-title":"J Pharmacol Exp Ther"},{"key":"793_CR45","volume-title":"Therapeutic drugs","author":"CT Dollery","year":"1991","unstructured":"Dollery CT (1991) Therapeutic drugs, 1st edn. Churchill Livingstone, Edinburgh","edition":"1"},{"issue":"3\u20134","key":"793_CR46","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/0376-8716(85)90067-5","volume":"14","author":"JW Lewis","year":"1985","unstructured":"Lewis JW (1985) Buprenorphine. Drug Alcohol Depend 14(3\u20134):363\u2013372","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"793_CR47","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/clpt.1989.147","volume":"46","author":"RE Johnson","year":"1989","unstructured":"Johnson RE, Cone EJ, Henningfield JE, Fudala PJ (1989) Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction. Clin Pharmacol Ther 46(3):335\u2013343","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"793_CR48","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1399-6576.1988.tb02772.x","volume":"32","author":"K Boysen","year":"1988","unstructured":"Boysen K, Hertel S, Chraemmer-Jorgensen B, Risbo A, Poulsen NJ (1988) Buprenorphine antagonism of ventilatory depression following fentanyl anaesthesia. Acta Anaesthesiol Scand 32(6):490\u2013492","journal-title":"Acta Anaesthesiol Scand"},{"issue":"6","key":"793_CR49","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/jat\/20.6.369","volume":"20","author":"JJ Kuhlman Jr","year":"1996","unstructured":"Kuhlman JJ Jr, Lalani S, Magluilo J Jr, Levine B, Darwin WD (1996) Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine. J Anal Toxicol 20(6):369\u2013378","journal-title":"J Anal Toxicol"},{"key":"793_CR50","first-page":"569","volume":"105","author":"EJ Cone","year":"1990","unstructured":"Cone EJ, Dickerson S, Darwin WD, Fudala PJ, Johnson RE (1990) Elevated drug saliva levels suggests a depot-like effect in subjects treated with sublingual buprenorphine. NIDA Res Monogr 105:569","journal-title":"NIDA Res Monogr"},{"issue":"1","key":"793_CR51","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0740-5472(03)00141-7","volume":"26","author":"J Ahmadi","year":"2004","unstructured":"Ahmadi J, Babaee-Beigi M, Alishahi M, Maany I, Hidari T (2004) Twelve-month maintenance treatment of opium-dependent patients. J Subst Abuse Treat 26(1):363\u2013366","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"793_CR52","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0376-8716(95)01186-2","volume":"40","author":"RE Johnson","year":"1995","unstructured":"Johnson RE, Eissenberg T, Stitzer ML, Strain EC, Liebson IA, Bigelow GE (1995) A placebo controlled clinical trial of buprenorphine as a treatment for opioid dependence. Drug Alcohol Depend 40(1):17\u201325","journal-title":"Drug Alcohol Depend"},{"issue":"9358","key":"793_CR53","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/S0140-6736(03)12600-1","volume":"361","author":"J Kakko","year":"2003","unstructured":"Kakko J, Svanborg KD, Kreek MJ, Heilig M (2003) 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet 361(9358):662\u2013668","journal-title":"Lancet"},{"issue":"5","key":"793_CR54","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1046\/j.1360-0443.2002.00090.x","volume":"97","author":"AL Krook","year":"2002","unstructured":"Krook AL, Brors O, Dahlberg J, Grouff K, Magnus P, Roysamb E et al (2002) A placebo-controlled study of high dose buprenorphine in opiate dependents waiting for medication-assisted rehabilitation in Oslo, Norway. Addiction 97(5):533\u2013542","journal-title":"Addiction"},{"issue":"4","key":"793_CR55","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1046\/j.1360-0443.1998.9344753.x","volume":"93","author":"W Ling","year":"1998","unstructured":"Ling W, Charuvastra C, Collins JF, Batki S, Brown LS Jr, Kintaudi P et al (1998) Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction 93(4):475\u2013486","journal-title":"Addiction"},{"issue":"1","key":"793_CR56","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0376-8716(00)80006-X","volume":"60","author":"PP Pani","year":"2000","unstructured":"Pani PP, Maremmani I, Pirastu R, Tagliamonte A, Gessa GL (2000) Buprenorphine: a controlled clinical trial in the treatment of opioid dependence. Drug Alcohol Depend 60(1):39\u201350","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"793_CR57","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1176\/appi.ajp.162.2.340","volume":"162","author":"RS Schottenfeld","year":"2005","unstructured":"Schottenfeld RS, Chawarski MC, Pakes JR, Pantalon MV, Carroll KM, Kosten TR (2005) Methadone versus buprenorphine with contingency management or performance feedback for cocaine and opioid dependence. Am J Psychiatry 162(2):340\u2013349","journal-title":"Am J Psychiatry"},{"issue":"Suppl 1","key":"793_CR58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000052036","volume":"4","author":"C Uehlinger","year":"1998","unstructured":"Uehlinger C, Deglon J, Livoti S, Petitjean S, Waldvogel D, Ladewig D (1998) Comparison of buprenorphine and methadone in the treatment of opioid dependence. Swiss multicentre study. Eur Addict Res 4(Suppl 1):13\u201318","journal-title":"Eur Addict Res"},{"issue":"3","key":"793_CR59","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0740-5472(03)00024-2","volume":"24","author":"J Ahmadi","year":"2003","unstructured":"Ahmadi J (2003) Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients. J Subst Abuse Treat 24(3):217\u2013220","journal-title":"J Subst Abuse Treat"},{"issue":"9","key":"793_CR60","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1046\/j.1360-0443.1999.94913376.x","volume":"94","author":"G Fischer","year":"1999","unstructured":"Fischer G, Gombas W, Eder H, Jagsch R, Peternell A, Stuhlinger G et al (1999) Buprenorphine versus methadone maintenance for the treatment of opioid dependence. Addiction 94(9):1337\u20131347","journal-title":"Addiction"},{"issue":"20","key":"793_CR61","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1001\/jama.1992.03480200058024","volume":"267","author":"RE Johnson","year":"1992","unstructured":"Johnson RE, Jaffe JH, Fudala PJ (1992) A controlled trial of buprenorphine treatment for opioid dependence. JAMA 267(20):2750\u20132755","journal-title":"JAMA"},{"issue":"6","key":"793_CR62","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1097\/00005053-199306000-00004","volume":"181","author":"TR Kosten","year":"1993","unstructured":"Kosten TR, Schottenfeld R, Ziedonis D, Falcioni J (1993) Buprenorphine versus methadone maintenance for opioid dependence. J Nerv Ment Dis 181(6):358\u2013364","journal-title":"J Nerv Ment Dis"},{"issue":"5","key":"793_CR63","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1001\/archpsyc.1996.01830050035005","volume":"53","author":"W Ling","year":"1996","unstructured":"Ling W, Wesson DR, Charuvastra C, Klett CJ (1996) A controlled trial comparing buprenorphine and methadone maintenance in opioid dependence. Arch Gen Psychiatry 53(5):401\u2013407","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"793_CR64","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1046\/j.1360-0443.2003.00335.x","volume":"98","author":"RP Mattick","year":"2003","unstructured":"Mattick RP, Ali R, White JM, O\u2019Brien S, Wolk S, Danz C (2003) Buprenorphine versus methadone maintenance therapy: a randomized double-blind trial with 405 opioid-dependent patients. Addiction 98(4):441\u2013452","journal-title":"Addiction"},{"issue":"3","key":"793_CR65","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s00213-005-2239-x","volume":"179","author":"S Neri","year":"2005","unstructured":"Neri S, Bruno CM, Pulvirenti D, Malaguarnera M, Italiano C, Mauceri B et al (2005) Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers. Psychopharmacology 179(3):700\u2013704","journal-title":"Psychopharmacology"},{"issue":"1","key":"793_CR66","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0376-8716(00)00163-0","volume":"62","author":"S Petitjean","year":"2001","unstructured":"Petitjean S, Stohler R, Deglon JJ, Livoti S, Waldvogel D, Uehlinger C et al (2001) Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug Alcohol Depend 62(1):97\u2013104","journal-title":"Drug Alcohol Depend"},{"issue":"7","key":"793_CR67","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1176\/ajp.151.7.1025","volume":"151","author":"EC Strain","year":"1994","unstructured":"Strain EC, Stitzer ML, Liebson IA, Bigelow GE (1994) Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am J Psychiatry 151(7):1025\u20131030","journal-title":"Am J Psychiatry"},{"key":"793_CR68","doi-asserted-by":"crossref","unstructured":"Mattick RP, Kimber J, Breen C, Davoli M (2008) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2:CD002207. doi: 10.1002\/14651858.CD002207.pub3","DOI":"10.1002\/14651858.CD002207.pub3"},{"issue":"5","key":"793_CR69","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1007\/s11920-007-0046-2","volume":"9","author":"M Fatseas","year":"2007","unstructured":"Fatseas M, Auriacombe M (2007) Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep 9(5):358\u2013364","journal-title":"Curr Psychiatry Rep"},{"issue":"2","key":"793_CR70","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0376-8716(01)00161-2","volume":"65","author":"X Thirion","year":"2002","unstructured":"Thirion X, Lapierre V, Micallef J, Ronfle E, Masut A, Pradel V et al (2002) Buprenorphine prescription by general practitioners in a French region. Drug Alcohol Depend 65(2):197\u2013204","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"793_CR71","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1300\/J069v24n03_02","volume":"24","author":"I Feroni","year":"2005","unstructured":"Feroni I, Peretti-Watel P, Paraponaris A, Masut A, Ronfle E, Mabriez JC et al (2005) French general practitioners\u2019 attitudes and prescription patterns toward buprenorphine maintenance treatment: does doctor shopping reflect buprenorphine misuse? J Addict Dis 24(3):7\u201322","journal-title":"J Addict Dis"},{"issue":"Suppl 1","key":"793_CR72","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1080\/10550490490440780","volume":"13","author":"M Auriacombe","year":"2004","unstructured":"Auriacombe M, Fatseas M, Dubernet J, Daulouede JP, Tignol J (2004) French field experience with buprenorphine. Am J Addict 13(Suppl 1):S17\u2013S28","journal-title":"Am J Addict"},{"issue":"Suppl 1","key":"793_CR73","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000052035","volume":"4","author":"J Bouchez","year":"1998","unstructured":"Bouchez J, Beauverie P, Touzeau D (1998) Substitution with buprenorphine in methadone- and morphine sulfate-dependent patients. Preliminary results. Eur Addict Res 4(Suppl 1):8\u201312","journal-title":"Eur Addict Res"},{"issue":"11","key":"793_CR74","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1046\/j.1360-0443.2003.00551.x","volume":"98","author":"S Kayemba-Kay\u2019s","year":"2003","unstructured":"Kayemba-Kay\u2019s S, Laclyde JP (2003) Buprenorphine withdrawal syndrome in newborns: a report of 13 cases. Addiction 98(11):1599\u20131604","journal-title":"Addiction"},{"issue":"1","key":"793_CR75","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0376-8716(00)00194-0","volume":"63","author":"RE Johnson","year":"2001","unstructured":"Johnson RE, Jones HE, Jasinski DR, Svikis DS, Haug NA, Jansson LM et al (2001) Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend 63(1):97\u2013103","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"793_CR76","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1046\/j.1360-0443.2000.95223910.x","volume":"95","author":"G Fischer","year":"2000","unstructured":"Fischer G, Johnson RE, Eder H, Jagsch R, Peternell A, Weninger M et al (2000) Treatment of opioid-dependent pregnant women with buprenorphine. Addiction 95(2):239\u2013244","journal-title":"Addiction"},{"issue":"1","key":"793_CR77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugalcdep.2004.11.013","volume":"79","author":"HE Jones","year":"2005","unstructured":"Jones HE, Johnson RE, Jasinski DR, O\u2019Grady KE, Chisholm CA, Choo RE et al (2005) Buprenorphine versus methadone in the treatment of pregnant opioid-dependent patients: effects on the neonatal abstinence syndrome. Drug Alcohol Depend 79(1):1\u201310","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"793_CR78","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1360-0443.2006.01321.x","volume":"101","author":"G Fischer","year":"2006","unstructured":"Fischer G, Ortner R, Rohrmeister K, Jagsch R, Baewert A, Langer M et al (2006) Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction 101(2):275\u2013281","journal-title":"Addiction"},{"issue":"9","key":"793_CR79","first-page":"1513","volume":"73","author":"DA Fiellin","year":"2006","unstructured":"Fiellin DA (2006) Buprenorphine: effective treatment of opioid addiction starts in the office. Am Fam Physician 73(9):1513\u20131514","journal-title":"Am Fam Physician"},{"issue":"3","key":"793_CR80","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/09595230412331289473","volume":"23","author":"J Bell","year":"2004","unstructured":"Bell J, Byron G, Gibson A, Morris A (2004) A pilot study of buprenorphine-naloxone combination tablet (Suboxone) in treatment of opioid dependence. Drug Alcohol Rev 23(3):311\u2013317","journal-title":"Drug Alcohol Rev"},{"key":"793_CR81","unstructured":"Naomi Study Team (2009) Reaching the hardest to reach\u2014treating the hardest-to-treat. Summary of the primary outcomes of NAOMI. North American Opiate Medication Initiative, Vancouver & Montreal"},{"issue":"9","key":"793_CR82","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1046\/j.1360-0443.2002.00193.x","volume":"97","author":"N Metrebian","year":"2002","unstructured":"Metrebian N, Carnwath T, Stimson GV, Storz T (2002) Survey of doctors prescribing diamorphine (heroin) to opiate-dependent drug users in the United Kingdom. Addiction 97(9):1155\u20131161","journal-title":"Addiction"},{"issue":"8","key":"793_CR83","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1001\/archpsyc.1980.01780210035003","volume":"37","author":"RL Hartnoll","year":"1980","unstructured":"Hartnoll RL, Mitcheson MC, Battersby A, Brown G, Ellis M, Fleming P et al (1980) Evaluation of heroin maintenance in controlled trial. Arch Gen Psychiatry 37(8):877\u2013884","journal-title":"Arch Gen Psychiatry"},{"issue":"1\u20132","key":"793_CR84","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0379-0738(01)00448-0","volume":"121","author":"C Brehmer","year":"2001","unstructured":"Brehmer C, Iten PX (2001) Medical prescription of heroin to chronic heroin addicts in Switzerland\u2014a review. Forensic Sci Int 121(1\u20132):23\u201326","journal-title":"Forensic Sci Int"},{"issue":"1","key":"793_CR85","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1360-0443.2005.00937.x","volume":"100","author":"P Blanken","year":"2005","unstructured":"Blanken P, Hendriks VM, Koeter MW, Van Ree JM, Van den Brink W (2005) Matching of treatment-resistant heroin-dependent patients to medical prescription of heroin or oral methadone treatment: results from two randomized controlled trials. Addiction 100(1):89\u201395","journal-title":"Addiction"},{"key":"793_CR86","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1192\/bjp.bp.106.026112","volume":"191","author":"C Haasen","year":"2007","unstructured":"Haasen C, Verthein U, Degkwitz P, Berger J, Krausz M, Naber D (2007) Heroin-assisted treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 191:55\u201362","journal-title":"Br J Psychiatry"},{"key":"793_CR87","doi-asserted-by":"crossref","unstructured":"Ferri-Marica MF, Davoli M, Perucci-Carlo AA (2005) Heroin maintenance for chronic heroin dependents. Cochrane Database Syst Rev 2:CD003410. doi: 10.1002\/14651858.CD003410.pub2","DOI":"10.1002\/14651858.CD003410.pub2"},{"issue":"8","key":"793_CR88","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1111\/j.1360-0443.2005.001128.x","volume":"100","author":"H Eder","year":"2005","unstructured":"Eder H, Jagsch R, Kraigher D, Primorac A, Ebner N, Fischer G (2005) Comparative study of the effectiveness of slow-release morphine and methadone for opioid maintenance therapy. Addiction 100(8):1101\u20131109","journal-title":"Addiction"},{"issue":"8","key":"793_CR89","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1111\/j.1360-0443.2004.00764.x","volume":"99","author":"TB Mitchell","year":"2004","unstructured":"Mitchell TB, White JM, Somogyi AA, Bochner F (2004) Slow-release oral morphine versus methadone: a crossover comparison of patient outcomes and acceptability as maintenance pharmacotherapies for opioid dependence. Addiction 99(8):940\u2013945","journal-title":"Addiction"},{"issue":"11","key":"793_CR90","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/j.1360-0443.2008.02334.x","volume":"103","author":"A Kastelic","year":"2008","unstructured":"Kastelic A, Dubajic G, Strbad E (2008) Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression. Addiction 103(11):1837\u20131846","journal-title":"Addiction"},{"issue":"11","key":"793_CR91","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1176\/appi.ajp.2007.07050252","volume":"164","author":"D Carise","year":"2007","unstructured":"Carise D, Dugosh KL, McLellan AT, Camilleri A, Woody GE, Lynch KG (2007) Prescription OxyContin abuse among patients entering addiction treatment. Am J Psychiatry 164(11):1750\u20131756","journal-title":"Am J Psychiatry"},{"key":"793_CR92","first-page":"121","volume-title":"Maintenance treatment of heroin addcition. Evidence at the crossroads","author":"M Krausz","year":"2003","unstructured":"Krausz M (2003) Alternative opoids-maintenance treatment for opiate addicts with codeine and morphine. In: Waal H, Haga E (eds) Maintenance treatment of heroin addcition. Evidence at the crossroads. Cappelen Akademiske, Oslo, pp 121\u2013129"},{"issue":"12","key":"793_CR93","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00228-003-0561-y","volume":"58","author":"L Bachs","year":"2003","unstructured":"Bachs L, Skurtveit S, Morland J (2003) Codeine and clinical impairment in samples in which morphine is not detected. Eur J Clin Pharmacol 58(12):785\u2013789","journal-title":"Eur J Clin Pharmacol"},{"key":"793_CR94","doi-asserted-by":"crossref","unstructured":"Clark NC, Lintzeris N, Gijsbers A, Whelan G, Dunlop A, Ritter A, et al (2002) LAAM maintenance vs methadone maintenance for heroin dependence. Cochrane Database Syst Rev 2:CD002210. doi: 10.1002\/14651858.CD002210","DOI":"10.1002\/14651858.CD002210"},{"issue":"3","key":"793_CR95","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2165\/00003088-197601030-00004","volume":"1","author":"BA Berkowitz","year":"1976","unstructured":"Berkowitz BA (1976) The relationship of pharmacokinetics to pharmacological activity: morphine, methadone and naloxone. Clin Pharmacokinet 1(3):219\u2013230","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"793_CR96","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0196-0644(83)80343-6","volume":"12","author":"KA Handal","year":"1983","unstructured":"Handal KA, Schauben JL, Salamone FR (1983) Naloxone. Ann Emerg Med 12(7):438\u2013445","journal-title":"Ann Emerg Med"},{"key":"793_CR97","doi-asserted-by":"crossref","unstructured":"Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A (2006) Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 1:CD001333. doi: 10.1002\/14651858.CD001333.pub2","DOI":"10.1002\/14651858.CD001333.pub2"},{"issue":"4","key":"793_CR98","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jsat.2004.02.002","volume":"26","author":"EM Krupitsky","year":"2004","unstructured":"Krupitsky EM, Zvartau EE, Masalov DV, Tsoi MV, Burakov AM, Egorova VY et al (2004) Naltrexone for heroin dependence treatment in St. Petersburg, Russia. J Subst Abuse Treat 26(4):285\u2013294","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"793_CR99","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/j.1360-0443.1991.tb01859.x","volume":"86","author":"L San","year":"1991","unstructured":"San L, Pomarol G, Peri JM, Olle JM, Cami J (1991) Follow-up after a six-month maintenance period on naltrexone versus placebo in heroin addicts. Br J Addict 86(8):983\u2013990","journal-title":"Br J Addict"},{"issue":"12","key":"793_CR100","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0006-3223(94)91240-8","volume":"35","author":"EN Shufman","year":"1994","unstructured":"Shufman EN, Porat S, Witztum E, Gandacu D, Bar-Hamburger R, Ginath Y (1994) The efficacy of naltrexone in preventing reabuse of heroin after detoxification. Biol Psychiatry 35(12):935\u2013945","journal-title":"Biol Psychiatry"},{"issue":"6","key":"793_CR101","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0740-5472(97)00020-2","volume":"14","author":"JW Cornish","year":"1997","unstructured":"Cornish JW, Metzger D, Woody GE, Wilson D, McLellan AT, Vandergrift B et al (1997) Naltrexone pharmacotherapy for opioid dependent federal probationers. J Subst Abuse Treat 14(6):529\u2013534","journal-title":"J Subst Abuse Treat"},{"issue":"3","key":"793_CR102","first-page":"247","volume":"47","author":"D Ladewig","year":"1990","unstructured":"Ladewig D (1990) Naltrexone\u2014an effective aid in the psychosocial rehabilitation process of former opiate dependent patients. Ther Umsch 47(3):247\u2013250","journal-title":"Ther Umsch"},{"issue":"3","key":"793_CR103","doi-asserted-by":"crossref","first-page":"192","DOI":"10.2165\/00003495-198835030-00002","volume":"35","author":"JP Gonzalez","year":"1988","unstructured":"Gonzalez JP, Brogden RN (1988) Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 35(3):192\u2013213","journal-title":"Drugs"},{"issue":"9631","key":"793_CR104","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/S0140-6736(08)60954-X","volume":"371","author":"RS Schottenfeld","year":"2008","unstructured":"Schottenfeld RS, Chawarski MC, Mazlan M (2008) Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet 371(9631):2192\u20132200","journal-title":"Lancet"},{"key":"793_CR105","first-page":"5","volume":"9","author":"D Julius","year":"1976","unstructured":"Julius D (1976) NIDA\u2019s naltrexone research program. NIDA Res Monogr 9:5\u201311","journal-title":"NIDA Res Monogr"},{"issue":"9 Pt 2","key":"793_CR106","first-page":"39","volume":"45","author":"AM Washton","year":"1984","unstructured":"Washton AM, Pottash AC, Gold MS (1984) Naltrexone in addicted business executives and physicians. J Clin Psychiatry 45(9 Pt 2):39\u201341","journal-title":"J Clin Psychiatry"},{"key":"793_CR107","first-page":"333","volume":"19","author":"RE Willette","year":"1978","unstructured":"Willette RE (1978) The development of sustained action preparations of narcotic antagonists. NIDA Res Monogr 19:333\u2013339","journal-title":"NIDA Res Monogr"},{"key":"793_CR108","doi-asserted-by":"crossref","unstructured":"Lobmaier P, Kornor H, Kunoe N, Bjorndal A (2008) Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev 2:CD006140. doi: 10.1002\/14651858.CD006140.pub2","DOI":"10.1002\/14651858.CD006140.pub2"},{"issue":"2","key":"793_CR109","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archpsyc.63.2.210","volume":"63","author":"SD Comer","year":"2006","unstructured":"Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K et al (2006) Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry 63(2):210\u2013218","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"793_CR110","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1192\/bjp.bp.108.055319","volume":"194","author":"N Kunoe","year":"2009","unstructured":"Kunoe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M et al (2009) Naltrexone implants after in-patient treatment for opioid dependence: randomised controlled trial. Br J Psychiatry 194(6):541\u2013546","journal-title":"Br J Psychiatry"},{"issue":"10","key":"793_CR111","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1001\/archgenpsychiatry.2009.130","volume":"66","author":"GK Hulse","year":"2009","unstructured":"Hulse GK, Morris N, Arnold-Reed D, Tait RJ (2009) Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone. Arch Gen Psychiatry 66(10):1108\u20131115","journal-title":"Arch Gen Psychiatry"},{"issue":"5","key":"793_CR112","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1097\/00063110-200610000-00017","volume":"13","author":"B O\u2019Brien","year":"2006","unstructured":"O\u2019Brien B, Cody C (2006) Analgesia and sedation in the presence of a naltrexone implant: a novel pharmacological challenge. Eur J Emerg Med 13(5):315\u2013316","journal-title":"Eur J Emerg Med"},{"issue":"2\u20133","key":"793_CR113","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.drugalcdep.2007.03.008","volume":"90","author":"JG Bramness","year":"2007","unstructured":"Bramness JG, Kornor H (2007) Benzodiazepine prescription for patients in opioid maintenance treatment in Norway. Drug Alcohol Depend 90(2\u20133):203\u2013209","journal-title":"Drug Alcohol Depend"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0793-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-010-0793-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-010-0793-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:24:02Z","timestamp":1739895842000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-010-0793-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,19]]},"references-count":113,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["793"],"URL":"https:\/\/doi.org\/10.1007\/s00228-010-0793-6","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,19]]}}}